Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Sponsor
National University Hospital, Singapore
Study ID
NCT07565389
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Nasopharyngeal Carcinoma (NPC)

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ivonescimab 20 mg/kg — DRUG
    Subjects will receive intravenous ivonescimab at a dose of 20 mg/kg administered every 3 weeks until disease progression, intolerable toxicities, or withdrawal from the study.

Study Details

This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune checkpoint inhibitor and platinum-based chemotherapy.

Key Dates

Start date
May 31, 2026
Status verified
Feb 2026
Primary completion
May 31, 2031
Completion
May 31, 2031

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A & B
    We plan to enrol 32 patients with R/M NPC and who had failed prior platinum-based chemotherapy and anti-PD1 therapy in this study from (Cohort A) and we will have an additional cohort B consisting of 10 patients with R/M NPC and who had failed prior platinum-based chemotherapy, PD1-inhibitor and anti-angiogenic therapy.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Best response at 1 year ]

Central Contacts